ABOUT LUMAKRAS® (SOTORASIB)

HOW DOES LUMAKRAS® WORK?

Lumakras icon
  • LUMAKRAS® is specifically designed for tumors with the KRAS G12C mutation in non-small cell lung cancer (NSCLC)1
  • In tumors with this KRAS mutation, the protein remains mostly in an “on” position, and cells are continuously forced to grow2
  • LUMAKRAS® targets the mutated KRAS molecule and locks it in the “off” position. This may prevent tumor cell growth3
green-round-icon

If your non-small cell lung cancer is KRAS G12C positive and has been treated with a prior therapy, such as chemotherapy or immunotherapy, ask your doctor if LUMAKRAS® may be able to help.1

NEXT: CLINICAL TRIAL RESULTS
×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.